ChemLex has launched a self-driving drug discovery lab in Singapore after closing a $45 million funding round, betting that robots and artificial intelligence can compress years of lab work into weeks.
The new global headquarters and fully automated facility sit in Singapore’s one-north innovation district and are designed to run around the clock with minimal human intervention.
The move matters because AI-powered drug discovery is shifting from slides and pitch decks to physical infrastructure. ChemLex is not just selling software; it is wiring AI directly into automated “chemistry factories” that design, execute, and learn from experiments at industrial scale. If the model works, it could reshape how big pharma and biotech approach early-stage research.
Behind the launch is a market that is starting to take off. Analysts now expect the AI drug discovery segment to grow from a low single-digit billion-dollar market in the mid-2020s to tens of billions by the mid-2030s, as more of the industry shifts to algorithm-driven screening and design.